Healthcare
Belite Bio, Inc
BLTE$171.09+6.49%
Price is delayed.
Add to Watchlist
About Belite Bio, Inc
Belite Bio is a drug development company testing treatments for eye and liver diseases. Their main focus is a pill called Tinlarebant that they are testing in patients with Stargardt disease and geographic atrophy, two conditions that cause vision loss. They are also developing another experimental drug for fatty liver disease, liver inflammation, type 2 diabetes, and gout. The company was founded in 2016 and is based in San Diego.
Loading chart...
Members only
Full research is for ConvictionStocks members
Members read the rest of this page. Where we have it for this company, that is:
- What each number means, in plain English, with the Wall Street name where the two differ.
- A plain-English summary of the company.
- How many analysts cover it, and the count behind each rating.
- Recent news, dated.
Get the free weekly market digest
The week's biggest movers, every Sunday. No spam.
Look up another company
Related Research
More Healthcare stocks to explore